FDA Approves TOPIRAMATE — Upsher-Smith Laboratories, LLC

# FDA Approves Upsher-Smith's Topiramate Oral Formulation Upsher-Smith Laboratories, LLC received FDA approval for its oral topiramate formulation (NDA 205122) on March 11, 2014, adding to the competitive generic antiepileptic and migraine prevention market dominated by established players. The approval expands Upsher-Smith's neurological portfolio and allows the company to capture additional market share in the substantial topiramate segment, which generated hundreds of millions in annual sales across multiple therapeutic indications.